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Abstract
Background: To systematically investigate the relationship between CT morphological features and the presence of
epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC).
Methods: All studies about the CT morphological features of NSCLC with EGFR mutations published between
January 1, 2000 and March 15, 2015 were searched in the PubMed and EMBASE databases. Qualified studies were
selected according to inclusion criteria. The frequency of EGFR mutations and CT features of ground-glass opacity
(GGO) content, tumor size, cavitation, air-bronchogram, lobulation, and spiculation were extracted. The relationship
between EGFR mutations and each of these CT features was tested based upon the weighted mean difference or
inverse variance in the form of an odds ratio at a 95% confidence interval using Forest Plots. The publication bias
was examined using Egger’s test.
Results: A total of 13 studies, consisting of 2146 NSCLC patients, were included, and 51.12% (1097/2146) of patients
had EGFR mutations. The EGFR mutations were present in NSCLC with part-solid GGO in contrast to nonsolid GGO
(OR = 0.49, 95% CI = 0.25–0.96, P = 0.04). Other CT features such as tumor size, cavitation, air-bronchogram,
lobulation and spiculation did not demonstrate statistically significant correlation with EGFR mutations individually
(P = 0.91; 0.67; 0.12; 0.45; and 0.36, respectively). No publication bias among the selected studies was noted in this
meta-analysis (Egger’s tests, P > 0.05 for all).
Conclusion: This meta-analysis demonstrated that NSCLC with CT morphological features of part-solid GGO tended
to be EGFR mutated, which might provide an important clue for the correct selection of patients treated with
molecular targeted therapies.
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Background
Lung cancer is the leading cause of cancer-related deaths
globally, with an estimated 1,589,900 deaths in 2012 [1].
In the USA, over 220,000 patients with lung cancers were
diagnosed in 2015, and the 5-year overall survival was only
18% [2]. In China, approximately 733,300 patients with
lung cancers were diagnosed and 610,200 of them died in
2015; the number of deaths would be anticipated to be
more than one million by 2025 [3, 4]. Most patients with
lung cancer are diagnosed at advanced stages and are not
eligible for curative surgery due to the lack of early specific
signs and symptoms; hence, the prognoses for these pa-
tients are usually poor [5–7].
In recent years, the molecular targets of lung cancer,
especially for the main histological type non-small cell
lung cancer (NSCLC), have been investigated, including
epidermal growth factor receptor (EGFR), Kirsten rat
sarcoma viral oncogene homolog (KRAS), anaplastic
lymphoma kinase (ALK), human epidermal growth
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factor receptor 2 (HER2), etc. Targeted therapy has
shown promising benefits for patients who inherited
mutations in these genes [8–13]. EGFR, one of these
molecular targets with a high frequency of mutation, is a
transmembrane receptor tyrosine kinase involved in the
signaling pathways regulating cell proliferation, apop-
tosis, angiogenesis, and invasion [14, 15]. The most
common EGFR mutations have been shown to be found
in adenocarcinoma in female non-smoker of East Asian
ethnicity [8, 9], and the mutation rate is reported to be
27–56% in this population compared with 8–10% world-
wide [9, 16]. Patients with EGFR mutations demon-
strated a high response rate of approximately 70% to
EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. The
progression-free survival (PFS) has been reported to
reach 9 to 13 months when EGFR-TKIs are administered
as the first-line therapy [17–19]. Two types of method
for detecting EGFR mutations are currently available:
“screening” assays that detect overall mutations, such as
Next Generation Sequencing (NGS) and Sanger Sequen-
cing, and “specific” methods that detect specific known
mutations using different approaches, such as Roche’s
EGFR Mutation Test and Life Technologies’ SNaPShot
[20, 21]. However, both methods are costly and not feas-
ible in every lung cancer clinic. CT is a routinely used
and relatively cost-effective modality in the diagnosis of
lung cancer that presents various imaging features, some
of which have been reported to relate with certain histo-
pathological types [22], while these types have been
identified to correlate with EGFR mutations [23]. There-
fore, we hypothesized that specific CT features of
NSCLC were associated with EGFR mutations. In this
study, we systematically searched the current medical lit-
erature and comprehensively examined the relationship
between CT features and the presence of EGFR muta-
tions in NSCLC patients.
Methods
This meta-analysis was carried out in accordance to the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement (Additional file 1.
Checklist S1) [24]. The primary procedures were as
follows:
1. Search strategy
We searched PubMed and EMBASE (Excerpta
Medica database) for all articles about
radiogenomics of NSCLC with EGFR mutation
published between January 1, 2000 and March 15,
2015. The medical subject terms and key words used
for search were “epidermal growth factor receptor”,
“EGFR”, “lung cancer”, “lung carcinoma”, “CT”, and
“imaging” in the Boolean expression: ((epidermal
growth factor receptor) OR EGFR) AND ((lung
cancer) OR (lung carcinoma)) AND ((CT) OR
(imaging)) without language restrictions. Related
articles, including those from the references, were
also searched.
2. Inclusion/exclusion criteria
Qualified studies were included if they satisfied the
following criteria: (1) NSCLC was diagnosed based
upon either pathological or cytological results; (2)
EGFR mutations were determined by fluorescence in
situ hybridization (FISH), immunohistochemistry
(IHC), polymerase chain reaction (PCR), or any
combination of the above-mentioned methods; (3)
CT features of tumors were studied before the deter-
mination of EGFR mutation or afterwards in a
blinded manner; (4) the association between EGFR
mutation status and CT features was investigated;
and (5) studies were available with full text articles.
The studies were excluded if (1) there was duplicate
data or insufficient data; and (2) the articles were ab-
stracts, comments, narrative reviews, or editorials
without full-text available.
3. Data extraction
The following information was independently
extracted from all eligible articles by two
investigators (Cheng Z.H. and Shan F.): first author’s
name, year of publication, country of origin, number
of enrolled patients, frequency of the EGFR gene
mutation, detection method, histologic type, and CT
features, which included proportion of ground-glass
opacity (GGO), tumor size, cavitation, air-
bronchogram, lobulation, and spiculation. GGO was
defined as hazy intensity with visible brochovascular
markings in the lung window setting [25]. The pro-
portion of GGO was calculated according to the ra-
tio of the maximum length of GGO to that of total
tumor in the largest cross section and classified as
follows: (1) solid tumor: GGO = 0%; (2) part-solid
GGO: 0% < GGO <50%, and 50% ≤GGO <100%; (3)
non-solid GGO = 100% [26–29]. Tumor size was
measured in the largest cross section by averaging
the length and width, and in the largest tumor if
multiple tumors were present [26]. Cavitation was
defined as airspace within the tumor at the time of
diagnosis and prior to biopsy or treatment [30]. Air-
bronchogram was defined as air-filled small foci or
branches within the solid part of tumor [31]. Lobula-
tion was defined as the shallow wavy contour of a
tumor’s surface with exception of the portion adja-
cent to pleura [32]. Spiculation was defined as sharp
linear projections from the tumor [31]. All the above
features were analyzed for each tumor prior to treat-
ment. Any discrepancies between the independent
extractions of data were resolved by a mutual review
of the original articles for a consensus agreement.
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4. Statistical analysis
All statistical analyses were performed using the
Review Manager (RevMan, version 5.3.5) and
STATA (version 12.0). All statistical tests were two-
sided, and the significance level was set at 0.05.
The association between the CT features and EGFR mu-
tations of NSCLC was assessed based upon the weighted
mean difference (WMD) or inverse variance (IV) in the
form of odds ratio (OR) [33] at a 95% confidence interval
(95% CI). Specifically, (1) the association between GGO
content (containing GGO or not; non-solid, part-solid or
solid; proportion of GGO) and EGFR mutation (some sub-
types when available were also included) was tested by
WMD for overall effect. (2) Association between tumor size
and EGFR mutation was tested by IV for overall effect. (3)
Association between tumor cavitation, air-bronchogram,
lobulation, spiculation and EGFR mutation was tested by
WMD for overall effect.
Heterogeneity was examined by the Chi-square
based Q test. Inconsistency index (I2) ranging from 0
to 100% was utilized to define the inter-trial variabil-
ity due to heterogeneity rather than to sampling error
within the study [34]. A random-effects model based
on the Der Simonian and Laird method was adopted
if I2 was above 50%, which indicated the presence of
a significant heterogeneity; otherwise, a fixed-effect
model based on the Mantel-Haenszel method was
used if I2 was under 50%.
The publication bias was examined using Funnel plots
and Egger’s tests. Deviation from the funnel-shaped dis-




A total of 2146 patients with NSCLC from 13 qualified
articles were included [26–31, 35–41], of whom 1097
patients (51.12%) had EGFR mutations. Most studies
(11/13) were from Asia, including Korea (3), Japan (5),
and China (3); the other two studies were conducted in
the U.S.A. The EGFR detection techniques included
PCR (8 studies), FISH (1 study), IHC (2 studies), PCR
and FISH (1 study), PCR and IHC (1 study). The flow
diagram of the selection process of the eligible studies
is shown in Fig. 1.
Table 1 summarizes the basic characteristics of all
qualified articles. The rate of detection of EGFR muta-
tions ranged from 23.83 to 73.91% based on 13 qualified
articles, and the average incidence was 49.00% in 2146
patients with NSCLC.
Fig. 1 Flow diagram of the study selection process
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GGO and EGFR mutations
Tumors with or without GGO and EGFR mutation
Eight studies were available for investigation of the re-
lationship between tumors with and without GGO and
EGFR mutation. Out of a total of 505 tumors with
GGOs and 1041 solid tumors (tumors without GGO),
EGFR mutation was detected positively in 56.24%
(284/505) and 52.45% (546/1041) of cases, respect-
ively. Figure 2a summarizes the findings. A random-
effects model was utilized for the meta-analysis due to
significant heterogeneity (I2 = 78%, P < 0.0001). No sta-
tistically significant difference was found between tu-
mors with and without GGO and EGFR mutation in
patients with NSCLC (pooled OR = 1.55, 95% CI =
0.88–2.73, P = 0.13).
Tumors with or without GGO and EGFR mutation subtypes
Three studies were available for investigation of the rela-
tionship between tumors with and without GGO and
the EGFR mutation subtypes, which included a total of
252 tumors with GGOs and 721 solid tumors. EGFR
exon 21 mutation (L858R) was detected in 31.35% (79/
252) and 30.93% (223/721) of cases, while EGFR exon 19
deletion was confirmed in 25% (63/252) and 24.97%
(180/721) of cases, respectively. Figure 2b and c
summarize the findings. A random-effect model and a
fixed-effect model was chosen for meta-analysis as sig-
nificant heterogeneity and no significant heterogeneity
was observed, respectively (I2 = 58%, P = 0.09; I2 = 0%, P
= 0.76). No statistically significant differences were found
between tumors with and without GGO in patients with
NSCLC having inherited these two mutation subtypes
(OR = 0.93, 95% CI = 0.46-1.89, P = 0.84; OR = 0.90, 95%
CI = 0.63–1.28, P = 0.54, respectively).
Non-solid GGO, part-solid GGO, solid tumor and EGFR
mutation
Five available articles were included for investigation of
the relationship between non-solid and part-solid
GGOs and EGFR mutation status. Out of a total of 64
tumors with non-solid GGOs and 162 part-solid GGOs,
EGFR mutations were detected in 45.31% (29/64) and
61.73% (100/162) of cases, respectively. Figure 3a sum-
marizes the findings. A fixed-effects model was used
for meta-analysis as no significant heterogeneity was
observed (I2 =6%, P = 0.37). The EGFR mutation rate
was significantly higher in tumors with part-solid
GGOs compared with pure ones (pooled OR = 0.49,
95% CI = 0.25–0.96, P = 0.04).
Four studies were available to study the relationship
between non-solid GGOs and solid tumors or part-
solid GGOs and solid tumors and the EGFR mutation
status. A total of 50 non-solid GGOs, 151 part-solid
GGOs and 249 solid tumors were found to have
EGFR mutations in 48% (24/50), 56.29% (85/151), and
43.37% (108/249) of cases, respectively. Figure 3b and
c summarize the findings. No statistically significant
differences were observed between non-solid and solid
tumors or part-solid and solid tumors and the EGFR
mutation status, respectively (I2 = 78%, pooled OR =
1.10, 95% CI = 0.14–8.55, P = 0.93; I2 = 86%, pooled
OR = 1.98, 95% CI = 0.55–7.09, P = 0.30, respectively).
Proportion of GGO and EGFR mutation
Four studies investigated the relationship between tu-
mors with a proportion of GGO less than or no less than
50% and EGFR mutation. Of a total of 264 tumors in the
former group and 114 in the latter, EGFR mutations
were detected in 50.38% (133/264) and 26.32% (30/114)
of cases, respectively. Figure 3d summarizes the findings.
Table 1 Summary of qualified studies
Study Year Source of Patient Stage No Frequency Method
Lee Y, et al. 2013 Korea I 214 23.83% (51/214) IHC
Lee HJ, et al. 2013 Korea I–III 153 54.25% (83/153) PCR, FISH
Park EA, et al. 2009 Korea I–IV 132 40.15% (53/132) FISH
Glynn C, et al. 2010 U.S.A UN 64 32.81% (21/64) PCR
Aoki T, et al. 2012 Japan UN 25 40.00% (10/25) PCR, IHC
Yano M, et al. 2006 Japan I–III 80 47.50% (38/80) PCR
Yoshida Y, et al. 2007 Japan I 23 73.91% (17/23) PCR
Hsu KH, et al. 2011 Taiwan I 162 64.20% (104/162) PCR
Sugano M, et al. 2011 Japan I–III 136 41.18% (56/136) PCR
Onn A, et al. 2005 U.S.A I 72 66.67% (48/72) IHC
Usuda K, et al. 2014 Japan I–IV 148 39.19% (58/148) PCR
Yang Y, et al. 2015 China 0–IV 788 60.91% (480/788) PCR
Hsu JS, et al. 2014 Taiwan III–IV 149 52.35% (78/149) PCR
Notes: UN unknown, IHC immunohistochemistry, PCR polymerase chain reaction, FISH fluorescent in situ hybridization
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A random-effects model was utilized for meta-analysis
due to significant heterogeneity (I2 = 94%, P < 0.00001).
No statistically significant difference was found between
these two groups and EGFR mutation (pooled OR =
4.13, 95% CI = 0.31–54.28, P = 0.28).
Other morphological features and EGFR mutation
Tumor size and EGFR mutation
Five studies investigated the relationship between tumor
size and EGFR mutation status: a total of 299 NSCLCs
with average size ranging from 1.92 to 2.7 cm with inher-
ited EGFR mutation and 433 tumors measuring between
1.43 and 3.74 cm without EGFR mutation were pooled
into the meta-analysis. Figure 4a summarizes the findings.
A random-effects model was adopted because of signifi-
cant heterogeneity (I2 = 92%, P < 0.00001). No statistically
significant difference was demonstrated between NSCLCs
with or without EGFR mutation and tumor size (pooled
WMD= −0.04, 95% CI = −0.73–0.66, P = 0.91).
Tumor cavitation and EGFR mutation
Four studies investigated on the relationship between
tumor cavitation and EGFR mutation status. A total of
23 out of 211 NSCLCs had cavitation with EGFR muta-
tion (10.90%) compared to 33 out of 317 NSCLCs with-
out EGFR mutation (10.41%). Figure 4b presents the
findings. A fixed-effects model was adopted as no sig-
nificant heterogeneity was noted (I2 = 0%, P = 0.51). No
significant difference was observed between tumors with
or without cavitation and EGFR mutation (pooled OR =
1.15, 95% CI = 0.60–2.19, P = 0.67).
Other CT features and EGFR mutation
In regard to relationship between tumors with or without
air-bronchogram, lobulation, and spiculation and EGFR
mutation, Fig. 4c, d, and e summarize the findings, re-
spectively. The meta-analyses showed no significant differ-
ences between tumors with or without these CT features
and EGFR mutation (P = 0.12, 0.45, and 0.36, respectively).
Fig. 2 Forest plots of the studies comparing tumors with and without GGO and EGFR mutation (notes: events, tumors with EGFR mutation; total,
all tumors with and without EGFR mutation). a No association was found between NSCLC with and without GGO content and overall EGFR
mutation. b No association was found between NSCLC with and without GGO content and EGFR exon 21 mutation (L858R). c No association was
found between NSCLC with and without GGO content and EGFR exon 19 deletion
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Fig. 3 Forest plots of studies on the association between GGO volume and EGFR mutation. a Mixed GGO (part-solid GGO) was EGFR mutated much
more commonly than pure GGO (non-solid GGO). b–c No association was found between pure or mixed GGO or solid tumor of NSCLC and EGFR
mutation. d No association was found between GGO with percentages (pGGO) less than or greater than 50% of NSCLC and EGFR mutation
Cheng et al. BMC Medical Imaging  (2017) 17:5 Page 6 of 10
Fig. 4 Forest plots of studies on the association between other morphological features of NSCLC and EGFR mutation. a No association was
found between tumor size and EGFR mutation. b–e No association was found between other morphological features, such as cavitation,
air-bronchogram, lobulation and spiculation, and EGFR mutation
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No publication bias was noted in this meta-analysis
(Egger’s test, P > 0.05 for all). The summarized results
are shown in Table 2.
Discussion
This meta-analysis investigated the radiogenomics of
NSCLCs inherited with EGFR mutation and the results
revealed that NSCLCs with part-solid GGOs rather than
non-solid ones tended to be EGFR mutated. Other CT
features such as tumor size, cavitation, air-bronchogram,
lobulation and spiculation were not correlated with
EGFR mutation.
The determination of the EGFR mutation status is cru-
cial for the personalized treatment in patients with lung
cancer and provides a molecular target that may be
treated using anti-EGFR drugs. However, the successful
detection of EGFR mutation is limited due to either insuf-
ficient pathological tissue collected by invasive aspiration
or precluded due to the high cost of molecular examin-
ation. Therefore, a noninvasive and cost-effective modality
is preferred. Based upon the reports that GGOs mani-
fested on thin-section CT have been found to be associ-
ated with certain histopathological types, such as atypical
adenomatous hyperplasia (AAH), adenocarcinoma in situ
(AIS, previously known as bronchioloalveolar carcinoma
(BAC)), and minimally invasive adenocarcinoma (MIA,
previously known as adenocarcinoma with a predominant
BAC component (ABAC)) [22], and that EGFR mutation
is frequently detected in these pathological subtypes, we
sought to study whether the detection of GGO on CT cor-
relates with EGFR mutation.
Although many retrospective studies have reported
that GGO was more frequent in tumors with EGFR
mutation [28, 37, 39–41], this meta-analysis revealed
that NSCLC with or without GGO did not differ in
terms of their EGFR mutation status. A possible explan-
ation may be the heterogeneity of the study population
related to some demographic or clinical features. Just as
Sugano M et al. [29] reported that there was no signifi-
cant association between GGO and EGFR mutation, but
that the EGFR mutation occurred more frequently in
male patients with GGO, this gender difference may be
accounted for by cross-talk between EGFR and estrogen
receptors [42]. Such subgroup analysis was not per-
formed in this meta-analysis because of the lack of quali-
fied studies available. Additionally, the two most
common activating mutation subtypes, short in-frame
deletions of exon 19, and point mutation (CTG to CGG)
in exon 21 at nucleotide 2573 (L858R) [43], did not dif-
fer in NSCLCs with or without GGO neither, although
Hsu et al. [36] found that a typical EGFR mutation, espe-
cially L858R, was more frequent in tumors (stage I) with
invasive solid pattern and significantly less in tumors
(stage I) with non-solid GGO. Again, the heterogeneity
in different tumor stages or histological subtypes may
have played a role in this aspect.
Regarding the proportion of GGO, this meta-analysis
demonstrated that NSCLCs with part-solid GGO rather
than the non-solid GGO tended to be EGFR mutated,
which is consistent with results of several other recent
studies indicating that mixed GGOs (part-solid GGOs),
especially those with a lower percentage of GGO had a
higher rate of EGFR TK domain mutation [27, 36, 41,
44]. A possible mechanism might be that EGFR, an
oncogene, played an important role in carcinogenesis
and tumor progression via activation of the RAS/RAF/
MEK/MAPK and the PI3K/AKT/mTOR pathways if
mutated [45, 46] and that the incidence of EGFR muta-
tion may be up-regulated by enhanced activation of cer-
tain pathways during the progression of tumors from a
non-solid GGO to a part-solid pattern.
In regard to the correlation between tumor size and
EGFR mutation status, a tendency was found that the
bigger the tumor was, the more frequent the EGFR mu-
tated [26, 28, 38, 40], although the present meta-analysis
did not show a statistically significant difference. This
was probably due to other potential confounders that
may have interacted with the tumor size. As Yano M
et al. [28] noted, GGO was more frequently observed
in EGFR mutation, and although a significant difference
was not reached individually, there was a significant differ-
ence if taking both tumor size and proportion of GGO
into consideration. Other CT features such as cavitation,
air-bronchogram, lobulation and spiculation were also
examined in this meta-analysis; however, no correl-
ation with EGFR mutation was found. With more ac-
cumulated data in the future, a meta-regression may
Table 2 Summary of Egger’s tests
Meta-analysis Egger's test
t value P value
GGO (+/−) ~ EGFR −0.11 0.915
GGO (≥/<50%) ~ EGFR 2.05 0.177
GGO (pure/mixed) ~ EGFR 0.71 0.551
GGO (mixed/-) ~ EGFR 0.22 0.847
GGO (pure/-) ~ EGFR 1.03 0.490
GGO (+/−) ~ exon21 −2.00 0.295
GGO (+/−) ~ exon19 7.70 0.082
Size ~ EGFR −1.63 0.201
Cavitation (+/−) ~ EGFR −1.89 0.199
Air-bronchogram (+/−) ~ EGFR −0.31 0.787
Lobulation (+/−) ~ EGFR 0.50 0.703
Spiculation (+/−) ~ EGFR −1.89 0.310
Notes: GGO ground glass opacity, EGFR epidermal growth factor receptor; +
Indicating with; - indicating without; ≥/<50% indicating % GGO volume
greater than/equal to or less than 50%
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be utilized to further investigate the underlying inter-
active features.
There are some limitations in this meta-analysis. First,
the sample size in a few subgroups was small, thus the
test effect may be lower and a false negative finding
would be introduced. Second, as there were no random-
ized controlled trials (RCT) available and the majority of
studies were retrospective, this may have introduced a
selection bias that could influence the final overall effect.
Third, CT scanning parameters and EGFR mutation de-
tection methods were heterogeneous across the retrieved
studies, and this may have increased the risk of inter-
study heterogeneity. Lastly, meta-regression analysis was
not performed due to the small number of subgroups.
Conclusions
In conclusion, this meta-analysis demonstrated that
EGFR mutation tended to be inherited in NSCLCs with
part-solid GGOs compared tumors with non-solid GGO
pattern. There was no correlation between EGFR muta-
tion and other CT features such as tumor size, cavita-
tion, air-bronchogram, lobulation and spiculation. As
most eligible studies were retrospectively performed and
had a relatively small sample size, future prospective
studies with a larger sample size are warranted for fur-
ther clarification of the relationship between molecular
markers and CT morphological characteristics, thus pro-
viding supporting evidence for potential molecular tar-
gets that may be treated using molecular drugs.
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